Follow
2cureX AB
Nasdaq First North Sweden (Sweden)
2cureX AB is a biotech company. The company is engaged in improving treatment efficiency mainly for cancer patients. It is involved in developing product namely IndiTreat, which is a technology for the treatment of colorectal, ovarian, and kidney cancers.
Sector:
HEALTH CARE
>
Biotechnology
Sector:
TECHNOLOGY
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Type
Ticker
ISIN
Market
SHARE
2CUREX
SE0010468124
Nasdaq First North Sweden
Sweden (SE)
Details of share in 2cureX AB with ticker 2CUREX
Status
Active
Order book id
Amount of instruments
12 420 000
Par value
Market cap
62 400 000.00 SEK
Currency
SEK
Segment
First North
First trading date
24 Oct 2017
Terms
Today, October 13, 2017, the subscription period of 2cureX AB's ("2cureX") new share issue will begin prior to scheduled listing on Nasdaq Stockholm First North. Subscription period expires on 27 October 2017. In the case of a fully subscribed new share issue, 2cureX is totaled approximately SEK 18.3 million before issue costs. Emission liquidity is intended to fund all preparatory activities for market launch of IndiTreat ™, which includes CE marking and ISO certification, sales organization building, revenue recognition strategies and establishment of additional validation sites in Germany, England and France. 2cureX has agreed in advance in writing about subscriptions of a total of approximately SEK 9.2 million, corresponding to approximately 50 percent of the issue fee. Memorandum, teaser and application for subscription of shares are available at 2cureX's (www.2curex.com ) and Sedermera Fondkommission ( www.sedermera.se ) and websites. In addition, there is the possibility to subscribe for shares with Bank ID on the Sedermera Fund Commission website. Sedermera Fondkommission is 2cureX's financial adviser in connection with the rights issue and the planned listing on Nasdaq Stockholm First North.
Type
Price
Pre-money valuation
Time
IPO
7.80 SEK
62.4M SEK
13 Oct - 27 Oct 2017
IPO in 2cureX AB
Market
Nasdaq First North Sweden
Subscription period
13 Oct - 27 Oct 2017
Subscription price
7.80 SEK
Price per share
7.80 SEK
Target to raise
18 330 000 SEK
Types
Share issue
Pre-money valuation
62 400 000 SEK
Subscription block size
1
Minimum subscription
700
Record date
13 Oct 2017
Offer status
Closed
Listing status
Listed
First trading date
24 Oct 2017
Issue terms
Today, October 13, 2017, the subscription period of 2cureX AB's ("2cureX") new share issue will begin prior to scheduled listing on Nasdaq Stockholm First North. Subscription period expires on 27 October 2017. In the case of a fully subscribed new share issue, 2cureX is totaled approximately SEK 18.3 million before issue costs. Emission liquidity is intended to fund all preparatory activities for market launch of IndiTreat ™, which includes CE marking and ISO certification, sales organization building, revenue recognition strategies and establishment of additional validation sites in Germany, England and France. 2cureX has agreed in advance in writing about subscriptions of a total of approximately SEK 9.2 million, corresponding to approximately 50 percent of the issue fee. Memorandum, teaser and application for subscription of shares are available at 2cureX's (www.2curex.com ) and Sedermera Fondkommission ( www.sedermera.se ) and websites. In addition, there is the possibility to subscribe for shares with Bank ID on the Sedermera Fund Commission website. Sedermera Fondkommission is 2cureX's financial adviser in connection with the rights issue and the planned listing on Nasdaq Stockholm First North.
Owners before
Povl-Andre Bendz Jørgen Drejer
Juan Farré
Simon Hesse Hoffmann Timm Jessen
Ulrich Spengler Ole Thastrup
Result of offer
The subscription period in 2cureX AB’s (“2cureX”) rights issue ended on 27. October 2017 with up to a maximum of approx. 18.3 MSEK ahead of the planned listing on First North. The rights issue was subscribed to approx. 65.2 MSEK including the subscription commitment, representing a subscription rate of about 356 percent. Through the new issue approximately 1700 new shareholders are added to 2cureX. The emission provides approximately 18.3 MSEK in proceeds before issue costs. The issue costs are estimated at approx. 1.7 MSEK. Sales notes are scheduled to be sent out today, 2. November, 2017. The first day of trading on Nasdaq OMX First North is, given the marketplace acceptance, estimated to be 24. November 2017.
Type
Price
Pre-money valuation
Time
New issue
11.95 SEK
123.68M SEK
09 May - 23 May 2019
Share issue in 2cureX AB
Market
Nasdaq First North Sweden
Subscription period
09 May - 23 May 2019
Subscription price
11.95 SEK
Price per share
11.95 SEK
Target to raise
24 736 500 SEK
Types
Share issue
Pre-money valuation
123 682 500 SEK
Subscription block size
Minimum subscription
Record date
03 May 2019
Offer status
Closed
Listing status
Listed
Issue terms
Preferential subscription 1:5. For each existing share one (1) subscription right is received. Five (5) subscription rights entitle to subscribe for one (1) new share. The public is also invited to subscribe for shares in the rights issue.
People
Number of Employees
9 people
Ole Thastrup
CEO
Povl-Andre Bendz
Chairman of the board
Ole Thastrup
Board member
Jørgen Drejer
Board member
Juan Farré
Board member
Simon Hesse Hoffmann
Board member
Timm Jessen
Board member
Ulrich Spengler
Board member
Company Details
Sector
HEALTH CARE, TECHNOLOGY

Address
Box 159
Zip code
261 22
City/district
Landskrona
Country
Sweden (SE)
Phones
Registration number
559128-0077
LEI code
549300SFOL75WIYF2O80
First trade date
24 Nov 2017
Registration date
05 Oct 2017
Short name
2cureX

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More